Sun Nuclear, a Mirion Medical (NYSE: MIR) company, is set to showcase a suite of new software and hardware solutions for radiation therapy quality assurance at the 2025 American Association of Physicists in Medicine (AAPM) Annual Meeting. The company’s portfolio expansion—centered around adaptive therapy support, AI-enhanced treatment planning, high-precision detectors, and radiation-tolerant monitoring tools—reflects its deepening focus on personalized, efficient, and safety-centric oncology workflows.
Scheduled for July 27–29 in Washington, D.C., the AAPM 2025 event will feature the formal debut of these innovations, with in-booth demonstrations and clinical discussions aimed at medical physicists and radiotherapy professionals. Sun Nuclear’s offerings arrive at a time when oncology care is shifting toward more personalized, adaptive treatments and increasingly relies on real-time imaging, precision dosimetry, and robust QA systems.
What is Sun Nuclear launching at AAPM 2025?
The company will spotlight four key technologies during the conference: AdaptCHECK, Plan AI, SunSILICON detectors, and evrCAM cameras. Each targets a critical step in the radiation therapy workflow.
AdaptCHECK is designed to streamline patient-specific quality assurance (QA) in adaptive therapy, especially for clinics using Varian Medical Systems Ethos Therapy. The software allows for secondary dose verification, plan-of-the-day recalculations, and anatomical adaptation without interrupting care. It integrates with the existing SunCHECKPatient QA workflow, enhancing continuity and auditability.
Plan AI, developed by Oncospace (now part of Sun Nuclear), is an artificial intelligence-based assistant that improves radiation therapy planning by delivering predictive, patient-specific guidance on achievable dosimetric goals. The software aims to reduce planning time and improve consistency by providing planners with upfront insight into optimal trade-offs. This innovation is well-positioned to address longstanding inefficiencies in plan standardization, especially in resource-constrained oncology departments.
SunSILICON detectors, successors to the widely used EDGE Detector, introduce silicon-based diodes optimized for both photon and electron dosimetry. These detectors are compatible with the SunSCAN 3D water phantom and designed to support high-precision modalities such as stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). SunSILICON P, a shielded variant, expands compatibility across photon field sizes.
evrCAM is a radiation-tolerant, pan-tilt-zoom camera tailored for treatment room integration. Built to resist degradation in high-radiation environments, it provides reliable patient video monitoring across all linear accelerator (linac) types. This camera addresses a growing concern in modern radiotherapy—the need for uninterrupted, high-resolution patient observation even during beam-on phases.
Why Sun Nuclear’s product refresh matters to the oncology QA market
The launch comes amid a broader shift in radiation oncology from traditional linear workflows to real-time adaptive models. Vendors are now racing to close gaps between treatment planning, verification, and delivery through smarter automation, AI, and tighter QA integration. By embedding AI-driven decision support (Plan AI) and adaptive verification capabilities (AdaptCHECK) into clinical workflows, Sun Nuclear aims to simplify what is otherwise a labor-intensive and error-prone process.
The medical physics market has seen increased demand for automated, interoperable QA solutions that can scale across different vendor platforms. Sun Nuclear’s strategy to align its QA tools with Varian and Elekta ecosystems is particularly notable. AdaptCHECK, for instance, supports Varian Ethos adaptive therapy, while SciMoCa—another offering highlighted at AAPM 2025—enables Monte Carlo-based verification for Elekta Unity MR-linac systems.
This dual compatibility positions Sun Nuclear as a vendor-neutral provider in a sector where many clinics operate multi-vendor infrastructures. As radiation oncology moves toward precision, speed, and safety, vendors capable of providing cross-platform integration are gaining favor with hospital procurement teams and clinical physicists.
How Plan AI fits into the competitive landscape for AI in treatment planning
AI-based planning assistants have become increasingly popular in radiotherapy. Major players such as RaySearch, Varian (via HyperSight), and Elekta (via ProKnow and MIM) are developing their own intelligent automation systems. Sun Nuclear’s Plan AI stands out by addressing a major clinician pain point—planning goal uncertainty—at the start of the process rather than during iteration. This preemptive guidance model may give Sun Nuclear an edge in clinics seeking to standardize and accelerate treatment planning timelines.
Clinical adoption of AI in radiation therapy planning is also being boosted by reimbursement incentives for higher-efficiency care models and staffing shortages in oncology departments. AI tools like Plan AI could therefore see strong institutional demand, particularly in community hospitals and mid-sized cancer centers.
What’s new in QA hardware: detectors and video systems
SunSILICON detectors represent a material shift in Sun Nuclear’s QA hardware lineup. With silicon-based sensors tuned for both small and large fields, the detectors meet the growing need for precision dosimetry in complex modalities like SBRT and IMRT. The inclusion of SunSILICON in cylindrical phantom workflows (via SunSCAN 3D) supports quick deployment in existing QA setups without compromising calibration integrity.
In tandem, the evrCAM solution addresses an operational challenge common in radiation treatment rooms—monitoring patients during active beam delivery. Traditional cameras often degrade due to radiation exposure, resulting in pixel loss and poor video fidelity. With its hardened design and low-light optimization, evrCAM provides clinicians with continuous visibility, aiding in patient reassurance and safety compliance.
Live education sessions to demonstrate clinical impact
Sun Nuclear will host multiple in-booth presentations during AAPM 2025 at booth #5000. These sessions will feature internal subject matter experts alongside prominent clinical physicists. Demonstrations will include live walk-throughs of the AdaptCHECK and Plan AI workflows, detector integration, and evrCAM room deployment examples.
These interactive sessions are designed not only to showcase product capabilities but to generate dialogue on clinical best practices and feedback for future R&D cycles. As hospital systems increasingly prioritize evidence-backed procurement, such education-driven engagements may become a key differentiator.
Executive perspective on Sun Nuclear’s product direction
Luis Rivera, President of Sun Nuclear and Executive Vice President of Mirion Medical, emphasized that the expanded product portfolio is aligned with the industry’s shift toward smarter and more patient-centric radiotherapy. He noted that the company’s advancements in adaptive-focused QA, AI-assisted planning, and durable monitoring systems were built in response to direct feedback from medical physicists working in diverse clinical settings.
Rivera highlighted that these innovations are not only designed to enhance treatment quality and workflow efficiency but also to future-proof radiotherapy practices amid evolving regulatory and technological standards. His comments reflect a broader industry momentum toward integrating software intelligence with physical QA systems to create more resilient, responsive, and scalable oncology infrastructures.
What’s next for Sun Nuclear and Mirion Medical?
Sun Nuclear’s latest launches reinforce Mirion Medical’s broader positioning in the radiation safety and medical technology space. While Sun Nuclear operates in the clinical radiotherapy segment, Mirion’s portfolio spans nuclear medicine, industrial radiation detection, and dosimetry solutions. The convergence of these verticals may unlock synergies, especially in data management and interoperability.
Analysts following the sector suggest that vendors offering both software and hardware—particularly with cross-platform adaptability—are better equipped to meet the nuanced demands of next-generation radiotherapy. Institutional buyers are increasingly looking for end-to-end vendors who can minimize integration risks while accelerating QA program adoption.
Further developments are expected in the integration of Sun Nuclear’s AI and QA platforms into broader Mirion systems, with a potential emphasis on cloud connectivity, cybersecurity standards for QA tools, and international market expansion.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
